Thursday, May 8, 2014
Publication and contact
EPH receptor B4 (EPHB4);
derived growth factor receptor B (PDGFRB;
Patient sample and mouse
studies suggest inhibiting PDGFRB cross talk with EPHB4 could help treat
alveolar rhabdomyosarcoma (aRMS). In aRMS cells from human patients and mouse
models, EPHB4 and PDGFRB were upregulated. In human and mouse aRMS cells, EPHB4-
and PDGFRB-targeting siRNA or the dual inhibitor Sprycel
decreased viability compared with nonspecific siRNA or the PDGFRB inhibitor Gleevec
In a mouse orthotopic model of aRMS, dasatinib increased survival compared
with imatinib or vehicle. Next steps include working with partner VasGene
Therapeutics Inc. to validate the findings in mice with
human tumor xenografts.
Bristol-Myers Squibb Co.
Pharmaceutical Co. Ltd. market Sprycel, a small molecule inhibitor
tyrosine kinase and Src
kinase, to treat acute lymphoblastic leukemia (ALL) and chronic myelogenous
Novartis AG markets
Gleevec, a BCR-ABL tyrosine kinase inhibitor, to treat CML, ALL and
gastrointestinal stromal tumors (GISTs).
Published online May 8, 2014
licensing status not applicable
Aslam, M.I. et al. Proc.
Natl. Acad. Sci. USA; published online
April 14, 2014;
Contact: Charles Keller, Oregon Health & Science
University, Portland, Ore.
Contact: Jeffrey W. Tyner, same affiliation as above
Contact: Brian J. Druker, same affiliation as above
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]